Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 10 people enrolled
- Started
- 22 Jun 2021
- Ended
- 8 May 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Gadoxetate disodium
- Gadobenate dimeglumine
- Record updated
- 25 September 2026
- Why it stopped
- Low Accrual
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Colorectal cancer patients
- Age 18-80 years
- No prior treatment including surgery
- Prior imaging with suspected liver metastasis
Who cannot take part
- Previous reaction to gadolinium contrast agents
- Non-MR safe implants or metallic foreign bodies
- History of claustrophobia or movement disorders likely to impact image quality
- eGFR < 30 ml/min/1.73 m2
- Age < 18 years or > 80 years
Where in United States
- University of Colorado HospitalAurora, United States
About the trial
What the trial wants to find out
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.
The 2 groups in the trial
- Gadoxetate disodium exam first, Gadobenate Dimeglumine exam secondExisting treatment, for comparison
The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver magnetic resonance imaging (MRI) for known or suspected colorectal cancer (CRC) metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-20 days, but in opposite order, determined randomly.
Treatment: Gadoxetate disodium and Gadobenate dimeglumine
- Gadobenate Dimeglumine exam first, Gadoxetate disodium exam secondTreatment being tested
The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRI for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-20 days, but in opposite order, determined randomly.
Treatment: Gadoxetate disodium and Gadobenate dimeglumine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Liver Magnetic Resonance (MR) With an Abbreviated Gadobenate Dimeglumine Hepatobiliary Phase Protocol in Comparison to Liver MR With Gadoxetate Disodium for the Detection of Hepatic Metastases
- Record updated
- 25 September 2026